Baby's hand holding its mother's finger


Latest News


Sera Prognostics Announces Conference Call and Webcast of Third Quarter 2021 Financial Results on November 9

October 27, 2021- The Company will host a corresponding conference call and live webcast to discuss operational highlights, financial results and key topics at 5:00 p.m. Eastern Time.

Sera Prognostics Appoints Dr. Paul Kearney As Chief Data Officer

September 28, 2021- Brings extensive data science, bioinformatics and proteomics experience to foster further product innovation and informed healthcare insights into pregnancy

Sera Prognostics Appoints Dr. Michael R. Foley As Chief Medical Officer

September 15, 2021- Dr. Foley will lead all medical activities for Sera as the company executes its vision to be the Pregnancy Company.

Sera Prognostics Announces Publication Of Health Economic Analysis Supporting PreTRM® Test-and-treat Strategy To Improve Maternal And Infant Health

September 14, 2021- Publication illustrates clinical benefit of combining PreTRM® testing with evidence-based interventions to improve neonatal health and reduce total health costs.

Sera Prognostics To Present At Oppenheimer Fall Healthcare Life Sciences & Med Tech Summit

September 13, 2021- Sera will present at the Oppenheimer Fall Healthcare Life Sciences & Med Tech Summit on Tuesday, September 21, 2021 at 8:15 a.m. Eastern Time.

Sera Prognostics Reports Second Quarter 2021 Financial Results

August 30, 2021- Sera announced financial results for the second quarter ended June 30, 2021.

Sera Prognostics’ PreTRM® Test and Treat Strategy Benefits Demonstrated by Results of Prospective, Randomized Controlled Intervention Trial Evaluating Clinical Utility

August 17, 2021- Study demonstrates positive impact of the company’s PreTRM® test and treat strategy on improving neonatal healthcare

Sera Prognostics Announces Pricing of Initial Public Offering

July 14, 2021 – Sera today announced the pricing of its initial public offering of 4,687,500 shares of its common stock at a price to the public of $16.00 per share.

Sera Prognostics and Anthem, Inc. Announce Commercial Partnership Leveraging Innovative Biomarker Test to Reduce Risk of Preterm Birth

May 19, 2021-The PreTRM® Test Is Designed to Build a Foundation for Healthy Communities One Baby at a Time

Evaluation Of Health And Economic Benefit Of The PreTRM® Test-and-treat Strategy To Improve Maternal And Infant Health Among Commercially Insured In The Us

May 18, 2021-Data presented at the ISPOR 2021 Conference illustrating clinical benefit as well as cost savings

Stay in Touch